Genentech and Curis' vismodegib is submitted for FDA OK

09/12/2011 | Xconomy

Roche Holding unit Genentech is seeking FDA approval of vismodegib, a skin cancer drug developed with Curis. Clinical data show that vismodegib significantly reduces tumors in patients with basal cell carcinoma. The oral treatment works by disrupting the hedgehog biological pathway.

View Full Article in:

Xconomy

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT